LLY Eli Lilly and Company Common Stock
$1287,96
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$685–$1293
99% of range
Calificación del Analista
BUY
38 analysts
Precio Objetivo
$1299
+1% upside
P/E (TTM)
46.8
ROE
101.2%
Margen de Beneficio Neto
31.7%
Acerca de Eli Lilly and Company Common Stock Descripción general de la empresa de Wikipedia
Eli Lilly and Company es una empresa farmacéutica estadounidense con sede en Indianápolis, Indiana. Fundada en 1876 por el coronel Eli Lilly, farmacéutico y veterano de la Guerra de Secesión estadounidense, la compañía ha sido pionera en el desarrollo y comercialización de medicamentos innovadores.
Leer más
Eli Lilly and Company es una empresa farmacéutica estadounidense con sede en Indianápolis, Indiana. Fundada en 1876 por el coronel Eli Lilly, farmacéutico y veterano de la Guerra de Secesión estadounidense, la compañía ha sido pionera en el desarrollo y comercialización de medicamentos innovadores.
Historia
En la década de 1920, Eli Lilly comercializó la primera preparación de insulina, extraída del páncreas de bovinos y porcinos, bajo el nombre comercial de Iletin, para el tratamiento de la diabetes. En los años 40, la compañía industrializó el proceso de fabricación de la penicilina. En los años 50, fabricó la primera vacuna contra la poliomielitis en conjunto con el laboratorio Parke-Davis de Detroit. En 1982, lanzó la primera insulina humana obtenida por ingeniería genética, denominada Humulin. La comercialización del antidepresivo Prozac (fluoxetina) a mediados de los años 80 posicionó a la empresa como una de las más reconocidas a nivel mundial.
Presencia global
Hasta diciembre de 2024, Eli Lilly contaba con aproximadamente 47,000 empleados en todo el mundo, un aumento del 9.3% respecto al año anterior. La compañía opera plantas de producción en nueve países, incluyendo Estados Unidos, Irlanda, Italia, Francia y España . Además, Eli Lilly ha anunciado planes para construir cuatro nuevas instalaciones de fabricación en Estados Unidos, representando la mayor inversión en manufactura farmacéutica en la historia del país.
Importancia económica
En 2024, Eli Lilly reportó ingresos anuales de aproximadamente $45 mil millones, con una proyección de ingresos entre $58 mil millones y $61 mil millones para 2025, impulsados por el crecimiento en las ventas de sus medicamentos para la pérdida de peso y la diabetes. La compañía cotiza en la Bolsa de Nueva York bajo el símbolo LLY y forma parte del índice S&P 500
.
Productos destacados
Psiquiatría y neurología
Prozac (fluoxetina): antidepresivo.
Strattera (atomoxetina): tratamiento para el TDAH.
Cymbalta (duloxetina): antidepresivo.
Zyprexa (olanzapina): antipsicótico atípico para esquizofrenia y trastorno bipolar.
Endocrinología
Humalog y Humulin: insulinas.
Trulicity (dulaglutida): agonista del receptor GLP-1.
Mounjaro (tirzepatida): agonista dual de los receptores GLP-1 y GIP.
Evista (raloxifeno): tratamiento para la osteoporosis.
Forteo (teriparatida): tratamiento para la osteoporosis.
Humatrope (somatropina): hormona de crecimiento.
Oncología
Alimta (pemetrexed): quimioterapia.
Gemzar (gemcitabina): quimioterapia.
Retsevmo (selpercatinib): tratamiento cáncer pulmón.
Cardiología y cuidados intensivos
ReoPro (abciximab): agente antiplaquetario.
Urología
Cialis (tadalafilo): tratamiento para la disfunción eréctil.
Otros
Humapen: dispositivo para la administración de insulina.
Nabilona: cannabinoide sintético.
Tiomersal: conservante utilizado en vacunas.
Investigación y desarrollo
Eli Lilly invirtió $9.3 mil millones en investigación y desarrollo en 2023, representando el 27.3% de sus ventas netas. La compañía cuenta con instalaciones de I+D en siete países y realiza investigaciones clínicas en más de 55 países.
Empleados y liderazgo
Eli Lilly ha sido reconocida por atraer y retener talento en los campos de la salud, gestión e investigación. En noviembre de 2024, la compañía anunció la incorporación de Jon Moeller, presidente y director ejecutivo de Procter & Gamble, a su junta directiva
.
Ernesto Bustamante, científico peruano.
Mitch Daniels, actual gobernador del Estado de Indiana y exdirector del Hudson Institute.
Roald Hoffmann, premio Nobel de Química.
Michael Johns, escritor de discursos de la Casa Blanca y analista político en la fundación Heritage.
Claude H. Nash, presidente de ViroPharma.
Peter Nicholas, cofundador de la Boston Scientific Corporation.
Randall L. Tobias, coordinador de la política de lucha contra el sida en el Departamento de Estado del gobierno de los Estados Unidos.
Aparte, han sido miembros de su Consejo de Administración:
George H. W. Bush, expresidente y vicepresidente de los Estados Unidos.
Martin Feldstein, economista de la Universidad de Harvard.
Kenneth Lay, exdirector de Enron (antes del escándalo Enron).
William Verity Jr., ex secretario de Estado de Comercio del gobierno de los Estados Unidos.
Controversias
La empresa ha enfrentado diversas controversias, incluyendo:
Investigaciones regulatorias: En 2021, el Departamento de Justicia de EE. UU. inició una investigación criminal sobre presuntas irregularidades en la fabricación y manipulación de registros en su planta de Branchburg, Nueva Jersey.
Demandas por discriminación: En 2022, una exempleada presentó una demanda alegando despido injustificado tras reportar problemas de fabricación.
Precios de medicamentos: Eli Lilly ha sido criticada por los altos precios de la insulina. En respuesta, la compañía anunció en 2023 una reducción del precio de su insulina más utilizada a $35 por mes.
Fuente: Wikipedia, CC BY-SA 4.0 · Ver en Wikipedia ↗
LLY Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$1287.95
Capitalización Bursátil
—
P/E (TTM)
46.8
BPA (TTM)
$22.95
Ingresos (TTM)
$65.18B
Rendimiento div.
—
ROE
101.2%
Deuda/Capital
1.5
Rango 52S
$685 – $1293
LLY Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$65.18B
2016-12-31
→
2025-12-31
BPA
$22.95
2016-12-31
→
2025-12-31
Flujo de caja libre
—
Márgenes
31.7%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
LLY
Mediana de Pares
P/E (TTM)
46.8
53.4
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
LLY
Mediana de Pares
Net Profit Margin (Margen de Beneficio Neto)
31.7%
-24.7%
ROA
21.6%
-30.6%
ROE
101.2%
-56.4%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
LLY
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
1.5
0.0
Current Ratio (Ratio corriente)
1.6
1.6
Quick Ratio (Ratio Rápido)
0.7
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
LLY
Mediana de Pares
Revenue YoY (Ingresos interanuales)
44.7%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
31.7%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
21.6%
—
EPS YoY (EPS interanual)
96.0%
—
Net Income YoY (Beneficio Neto interanual)
94.9%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
LLY
Mediana de Pares
Payout Ratio (Ratio de Pago)
26.1%
—
Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años
Rendimiento por Dividendo
—
Ratio de Pago
26.1%
CAGR de Dividendos a 5 años
—
| Fecha ex-dividendo | Monto |
|---|---|
| 14 de agosto de 2026 | $1,7300 |
| 15 de mayo de 2026 | $1,7300 |
| 13 de febrero de 2026 | $1,7300 |
| 14 de noviembre de 2025 | $1,5000 |
| 15 de agosto de 2025 | $1,5000 |
| 16 de mayo de 2025 | $1,5000 |
| 14 de febrero de 2025 | $1,5000 |
| 15 de noviembre de 2024 | $1,3000 |
| 15 de agosto de 2024 | $1,3000 |
| 15 de mayo de 2024 | $1,3000 |
| 14 de febrero de 2024 | $1,3000 |
| 14 de noviembre de 2023 | $1,1300 |
| 14 de agosto de 2023 | $1,1300 |
| 12 de mayo de 2023 | $1,1300 |
| 14 de febrero de 2023 | $1,1300 |
| 14 de noviembre de 2022 | $0,9800 |
| 12 de agosto de 2022 | $0,9800 |
| 13 de mayo de 2022 | $0,9800 |
| 14 de febrero de 2022 | $0,9800 |
| 12 de noviembre de 2021 | $0,8500 |
LLY Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
38 analistas
- Compra fuerte 11 28,9%
- Compra 19 50,0%
- Mantener 7 18,4%
- Venta 1 2,6%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
27 analistas · 2026-08-15
Mediana
$1344.00
Ahora
$1287.95
Mín
$850.00
Máx
$1600.00
Objetivo mediano
$1344.00
+4,4%
Objetivo medio
$1299.01
+0,9%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
1.2%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $8.38 | $6.07 | 2.3% |
| 31 de marzo de 2026 | $8.55 | $6.73 | 1.8% |
| 31 de diciembre de 2025 | $7.54 | $6.74 | 0.80% |
| 30 de septiembre de 2025 | $7.02 | $5.75 | 1.3% |
| 30 de junio de 2025 | $6.31 | $5.51 | 0.80% |
| 31 de marzo de 2025 | $3.34 | $3.05 | 0.29% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | |
| Cost of Revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B | $5.04B | $4.93B | |
| R&D Expense | · | · | · | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B | $5.10B | $5.31B | $4.80B | $4.73B | |
| SG&A Expense | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $5.98B | $6.53B | $6.53B | $6.62B | |
| Interest Expense | · | · | $486M | $332M | $340M | $360M | $401M | $242M | $225M | $185M | $161M | $149M | |
| Interest Income | · | $175M | $174M | $63M | $25M | $33M | $80M | $159M | $166M | $109M | $87M | $121M | |
| Other Non-op | $-571M | $-219M | $97M | $-14M | $51M | $-196M | $-57M | $-12M | $111M | $196M | $342M | $368M | |
| Pretax Income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.30B | $3.37B | $2.79B | $3.00B | |
| Income Tax | $5.09B | $2.09B | $1.31B | $562M | $574M | $1.04B | $628M | $530M | $2.39B | $636M | $382M | $610M | |
| Net Income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204M | $2.74B | $2.41B | $2.39B | |
| EPS (Basic) | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 | $-0.19 | $2.59 | $2.27 | $2.23 | |
| EPS (Diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | $-0.19 | $2.58 | $2.26 | $2.23 | |
| Shares (Basic) | 897,300,000 | 900,600,000 | 900,200,000 | 901,736,000 | 906,963,000 | 907,634,000 | 931,059,000 | 1,027,721,000 | 1,052,023,000 | 1,058,324,000 | 1,061,913,000 | 1,069,932,000 | |
| Shares (Diluted) | 899,300,000 | 904,100,000 | 903,300,000 | 904,619,000 | 911,681,000 | 912,505,000 | 935,684,000 | 1,033,667,000 | 1,052,023,000 | 1,061,825,000 | 1,065,720,000 | 1,074,286,000 | |
| EBITDA | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B |
Balance general 28
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B | $2.34B | $7.32B | $6.54B | $4.58B | $3.67B | $3.87B | |
| Short-term Investments | · | $155M | $109M | $145M | $90M | $24M | $101M | $88M | $1.50B | $1.46B | $785M | $955M | |
| Receivables | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B | $5.88B | $4.55B | $4.59B | $4.55B | $4.03B | $3.51B | $3.23B | |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B | $3.98B | $3.19B | $3.10B | $4.46B | $3.56B | $3.45B | $2.74B | |
| Prepaid Expense | $14.31B | $8.34B | $5.54B | $2.95B | $2.53B | $2.87B | $2.54B | $2.04B | $1.45B | $735M | $604M | $560M | |
| Other Current Assets | $147M | $266M | $150M | $7M | · | · | · | · | · | · | · | · | |
| Current Assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B | $13.71B | $20.55B | $19.20B | $15.10B | $12.57B | $11.93B | |
| PP&E (Net) | $24.68B | $17.10B | $12.91B | $10.14B | $8.99B | $8.68B | $7.87B | $8.00B | $8.83B | $8.25B | $8.05B | $7.96B | |
| PP&E (Gross) | · | $28.89B | $24.01B | $20.38B | $18.96B | $18.25B | $17.03B | $16.66B | $18.09B | $16.78B | $16.66B | $16.03B | |
| Accum. Depreciation | $12.56B | $11.79B | $11.10B | $10.23B | $9.98B | $9.57B | $9.16B | $8.67B | $9.26B | $8.53B | $8.61B | $8.07B | |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B | $3.77B | $3.68B | $1.37B | $4.37B | $3.97B | $4.04B | $1.76B | |
| Intangibles | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B | $7.45B | $6.62B | $1.07B | $4.03B | $4.36B | $5.03B | $2.88B | |
| Other Non-current Assets | $6.99B | $5.72B | $4.99B | $4.34B | $4.08B | $3.48B | $2.87B | $1.82B | $1.71B | $1.91B | $2.22B | $1.80B | |
| Total Assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B | $35.57B | $36.31B | |
| Accounts Payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B | $1.61B | $1.41B | $1.21B | $1.41B | $1.35B | $1.34B | $1.13B | |
| Short-term Debt | $0 | $4.34B | $6.19B | $1.50B | $0 | $0 | $1.49B | $499M | $2.70B | $1.30B | $0 | $2.68B | |
| Current Liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B | $12.48B | $11.78B | $11.89B | $14.54B | $10.99B | $8.23B | $9.74B | |
| Capital Leases | $1.14B | $971M | $948M | · | · | · | $487M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | $87M | $1.73B | $2.10B | $2.19B | $1.31B | · | · | · | · | |
| Other Non-current Liabilities | $3.97B | $3.48B | $2.24B | $1.82B | $1.64B | $1.71B | $1.50B | $1.36B | $1.55B | $2.23B | $1.75B | $2.28B | |
| Long-term Debt | · | $29.47B | $19.10B | $14.82B | $16.74B | $16.35B | $13.64B | · | · | $9.01B | $7.98B | · | |
| Total Debt | $40.87B | $32.86B | $24.51B | $16.24B | $15.35B | $16.59B | $15.31B | $12.14B | $12.64B | $9.67B | $7.97B | $8.05B | |
| Common Stock | $590M | $592M | $594M | $594M | $596M | $598M | $599M | $661M | $688M | $688M | $691M | $695M | |
| Retained Earnings | $24.47B | $13.54B | $10.31B | $10.04B | $8.96B | $7.83B | $4.92B | $11.40B | $13.89B | $16.05B | $16.01B | $16.48B | |
| Treasury Stock | · | $50M | $44M | $50M | $53M | $56M | $61M | $69M | $76M | $80M | $90M | $91M | |
| AOCI | $-2.88B | $-4.32B | $-4.33B | $-3.84B | $-4.34B | $-6.50B | $-6.52B | $-5.73B | $-5.72B | $-5.27B | $-4.58B | $-3.99B | |
| Stockholders' Equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B | $5.64B | $2.61B | $9.83B | $11.59B | $14.01B | $14.57B | $15.37B | |
| Liabilities + Equity | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B | $35.57B | $36.31B |
Flujo de Efectivo 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B | $1.43B | $1.38B | |
| Stock-based Comp | $626M | $646M | $629M | $371M | $343M | $308M | $312M | $280M | $281M | $255M | $218M | $156M | |
| Deferred Tax | $-1.71B | $-2.68B | $-2.34B | $-2.19B | $-802M | $-134M | $62M | $248M | $-832M | $440M | $-748M | $37M | |
| Amort. of Intangibles | $488M | $553M | $506M | $580M | $629M | $428M | $226M | $361M | $462M | $688M | $632M | $536M | |
| Other Non-cash | $-4.74B | $-1.50B | $-815M | $1.13B | $591M | $-1.19B | $-5.09B | $77M | $4.76B | $-78M | $-533M | $405M | |
| Operating Cash Flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B | $5.62B | $4.85B | $2.96B | $4.46B | |
| Investing Cash Flow | $-10.97B | $-9.30B | $-7.15B | $-3.76B | $-2.87B | $-2.26B | $-8.08B | $1.91B | $-3.78B | $-3.14B | $27M | $-3.91B | |
| Debt Issued | $13.17B | $11.42B | $3.96B | $0 | $2.41B | $2.06B | $6.56B | $2.48B | $2.23B | $1.21B | $4.45B | $993M | |
| Net Debt Issued | $12.39B | $10.75B | $3.96B | $-1.56B | $505M | $1.79B | $3.69B | $1.47B | $1.60B | $1.21B | $2.50B | $-42M | |
| Stock Repurchased | $4.11B | $2.50B | $750M | $1.50B | $1.25B | $500M | $4.40B | $4.15B | $300M | $600M | $750M | $800M | |
| Net Stock Activity | $-4.11B | $-2.50B | $-750M | $-1.50B | $-1.25B | $-500M | $-4.40B | $-4.15B | $-300M | $-600M | $-750M | $-800M | |
| Dividends Paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B | $2.13B | $2.10B | |
| Financing Cash Flow | $-2.21B | $1.23B | $3.50B | $-5.41B | $-4.13B | $-3.14B | $-2.32B | $-5.90B | $143M | $-560M | $-3.11B | $-166M | |
| Net Change in Cash | $4.00B | $449M | $752M | $-1.75B | $161M | $1.32B | $-5.66B | $1.46B | $1.95B | $916M | $-205M | $41M | |
| Taxes Paid | $10.81B | $6.56B | $5.56B | · | · | · | · | · | · | · | · | · |
Rentabilidad 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 13.2% | -0.89% | 12.9% | 12.1% | 12.2% | |
| Pretax Margin | 39.5% | 28.1% | 19.2% | 23.8% | 21.7% | 29.5% | 23.6% | 15.5% | 9.6% | 15.9% | 14.0% | 15.3% | |
| EBITDA Margin | 3.1% | 3.9% | 4.5% | 5.3% | 5.5% | 5.4% | 5.5% | 6.6% | 6.9% | 7.0% | 7.1% | 7.0% | |
| ROA | 21.6% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | -0.49% | 7.4% | 6.7% | 6.6% | |
| ROE | 101.2% | 84.8% | 48.9% | 63.6% | 76.3% | 150.2% | 133.8% | 30.2% | -1.6% | 19.2% | 16.1% | 14.5% |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | 0.9 | 1.1 | 1.2 | 1.4 | 1.2 | 1.7 | 1.3 | 1.4 | 1.5 | 1.1 | |
| Quick Ratio | 0.7 | 0.5 | 0.4 | 0.5 | 0.7 | 0.8 | 0.6 | 1.1 | 0.9 | 0.9 | 1.0 | 0.7 | |
| Debt / Equity | 1.5 | 2.3 | 2.3 | 1.5 | 1.7 | 2.9 | 5.9 | 1.2 | 1.1 | 0.7 | 0.5 | 0.5 | |
| LT Debt / Equity | 1.5 | 2.0 | 1.7 | 1.4 | 1.7 | 2.9 | 5.3 | 1.2 | 0.9 | 0.6 | 0.5 | 0.3 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | |
| Inventory Turnover | 1.0 | 1.3 | 1.4 | 1.6 | 1.9 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.7 | |
| Receivables Turnover | 4.5 | 4.5 | 4.3 | 4.2 | 4.5 | 4.7 | 4.9 | 5.0 | 5.3 | 5.6 | 5.9 | 5.9 |
Tasas de Crecimiento 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 44.7% | 32.0% | 19.6% | 0.79% | 15.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 31.7% | 16.7% | 11.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 21.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 96.0% | 101.9% | -15.9% | 12.8% | -9.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 49.3% | 24.1% | -5.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 27.6% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 94.9% | 102.1% | -16.1% | 11.9% | -9.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 49.0% | 23.8% | -5.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 27.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 14.9% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 6
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | |
| Net Income TTM | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204M | $2.74B | $2.41B | $2.39B | |
| P/E | 46.8 | 65.9 | 100.5 | 53.0 | 45.1 | 24.9 | 14.8 | 37.0 | -444.5 | 28.5 | 37.3 | 30.9 | |
| Earnings Yield | 2.1% | 1.5% | 0.99% | 1.9% | 2.2% | 4.0% | 6.8% | 2.7% | -0.22% | 3.5% | 2.7% | 3.2% | |
| Payout Ratio | 26.1% | 44.2% | 77.6% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | -1074.0% | 78.8% | 88.3% | 87.9% | |
| Annual Payout | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B | $2.13B | $2.10B |
Estado de resultados 15
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B | $9.50B | $8.31B | $6.96B | $7.30B | $6.94B | |
| Cost of Revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.23B | $2.40B | $2.17B | $2.17B | $1.67B | $1.79B | $1.86B | $1.81B | $1.63B | $1.55B | $1.58B | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | · | · | $2.36B | $1.99B | · | $1.80B | |
| SG&A Expense | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | $2.47B | $2.42B | $2.10B | $2.12B | $1.95B | $1.93B | $1.80B | $1.93B | $1.75B | $1.64B | $1.61B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $180M | · | $125M | $120M | $103M | · | $82M | |
| Interest Income | · | · | · | $65M | $40M | $48M | · | $48M | $37M | $46M | · | $49M | $46M | $34M | $26M | $20M | |
| Other Non-op | $269M | $-65M | $-287M | $-179M | $-90M | $-239M | $-219M | $-21M | $-8M | $29M | $108M | $-100.0K | $-13M | $2M | $-31M | $-19M | |
| Pretax Income | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B | $1.59B | $3.52B | $2.54B | $2.51B | $427M | $2.09B | $1.53B | $2.10B | $1.57B | |
| Income Tax | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697M | $628M | $618M | $550M | $293M | $319M | $485M | $326M | $185M | $159M | $114M | |
| Net Income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970M | $2.97B | $2.24B | $2.19B | $-57M | $1.76B | $1.34B | $1.94B | $1.45B | |
| EPS (Basic) | $7.95 | $8.27 | $7.41 | $6.22 | $6.30 | $3.07 | $4.90 | $1.08 | $3.29 | $2.49 | $2.43 | $-0.06 | $1.96 | $1.49 | $2.15 | $1.61 | |
| EPS (Diluted) | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 | $3.06 | $4.88 | $1.07 | $3.28 | $2.48 | $2.42 | $-0.06 | $1.95 | $1.49 | $2.14 | $1.61 | |
| Shares (Basic) | 892,400,000 | 894,500,000 | -1,796,200,000 | 896,900,000 | 897,900,000 | 898,700,000 | -1,802,100,000 | 901,000,000 | 900,900,000 | 900,800,000 | -1,800,300,000 | 899,800,000 | 899,700,000 | 901,000,000 | -1,802,964,000 | 900,700,000 | |
| Shares (Diluted) | 893,700,000 | 895,900,000 | -1,799,900,000 | 898,800,000 | 899,800,000 | 900,600,000 | -1,808,900,000 | 905,000,000 | 904,200,000 | 903,800,000 | -1,802,500,000 | 899,800,000 | 902,700,000 | 903,300,000 | -1,808,481,000 | 903,800,000 | |
| EBITDA | · | $509M | · | · | · | $463M | · | · | · | $401M | · | · | · | $362M | · | · |
Balance general 26
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B | $2.46B | · | $2.38B | $2.69B | $3.55B | · | $2.62B | |
| Short-term Investments | · | · | · | $122M | $170M | $127M | · | $149M | $140M | $126M | · | $113M | $135M | $123M | · | $125M | |
| Receivables | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B | $10.29B | $11.03B | $7.89B | · | $8.17B | $7.52B | $7.53B | · | $6.72B | |
| Inventory | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B | $6.48B | $6.10B | · | $4.90B | $4.80B | $4.54B | · | $3.83B | |
| Prepaid Expense | $15.37B | $13.63B | $14.31B | $20.25B | $18.02B | $14.65B | $8.34B | $8.25B | $7.14B | $6.35B | · | $5.25B | $4.53B | $3.58B | · | $2.74B | |
| Other Current Assets | $86M | $214M | $147M | $272M | $69M | $72M | $266M | $135M | $142M | $139M | · | · | · | · | · | · | |
| Current Assets | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B | $30.20B | $25.19B | · | $23.01B | $21.33B | $20.81B | · | $17.64B | |
| PP&E (Net) | $29.29B | $26.54B | $24.68B | $22.32B | $20.53B | $18.47B | $17.10B | $16.17B | $14.83B | $13.62B | · | $11.86B | $11.28B | $10.55B | · | $9.31B | |
| Accum. Depreciation | $13.10B | · | $12.56B | $12.41B | $12.55B | $12.15B | $11.79B | $11.82B | $11.43B | $11.23B | · | $10.77B | $10.63B | $10.49B | · | $10.07B | |
| Goodwill | $8.85B | $6.13B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B | $5.77B | $5.77B | $4.94B | · | $4.09B | $4.08B | $4.07B | · | $3.89B | |
| Intangibles | $18.11B | $7.37B | $6.52B | $6.45B | $5.91B | $6.01B | $6.17B | $6.54B | $6.64B | $6.76B | · | $6.78B | $6.90B | $7.09B | · | $7.12B | |
| Other Non-current Assets | $7.48B | $7.23B | $6.99B | $6.43B | $6.23B | $6.07B | $5.72B | $5.12B | $4.90B | $4.71B | · | $4.91B | $4.67B | $4.49B | · | $4.54B | |
| Total Assets | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B | $71.87B | $63.94B | · | $57.92B | $54.81B | $53.16B | · | $47.46B | |
| Accounts Payable | $6.11B | $5.03B | $5.38B | $4.26B | $4.08B | $3.44B | $3.23B | $2.89B | $2.92B | $2.47B | · | $2.44B | $2.47B | $2.02B | · | $1.68B | |
| Short-term Debt | · | · | $0 | · | · | · | $4.34B | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B | $24.67B | $27.12B | $18.60B | · | $22.00B | $18.91B | $16.01B | · | $15.65B | |
| Capital Leases | · | · | $1.14B | · | · | · | $971M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $172M | |
| Other Non-current Liabilities | $7.34B | $4.08B | $3.97B | $3.78B | $2.34B | $2.29B | $3.48B | $2.24B | $2.47B | $2.27B | · | $1.91B | $1.95B | $1.82B | · | $1.85B | |
| Total Debt | $47.86B | $39.37B | · | $40.87B | $34.18B | $34.50B | · | $29.05B | $23.73B | $24.56B | · | $17.92B | $18.16B | $18.88B | · | $14.14B | |
| Common Stock | $588M | $590M | $590M | $591M | $592M | $593M | $592M | $594M | $594M | $594M | · | $594M | $594M | $594M | · | $594M | |
| Retained Earnings | $31.89B | $29.51B | $24.47B | $22.25B | $17.38B | $15.10B | $13.54B | $13.63B | $13.18B | $12.55B | · | $10.31B | $10.37B | $10.64B | · | $10.01B | |
| Treasury Stock | · | · | · | $62M | $55M | $50M | · | $33M | $33M | $33M | · | $45M | $45M | $45M | · | $50M | |
| AOCI | $-2.76B | $-2.83B | $-2.88B | $-3.21B | $-3.72B | $-3.77B | $-4.32B | $-4.27B | $-4.38B | $-4.30B | · | $-3.78B | $-3.79B | $-3.78B | · | $-4.30B | |
| Stockholders' Equity | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.27B | $14.24B | $13.56B | $12.81B | · | $11.22B | $11.06B | $11.19B | · | $10.07B | |
| Liabilities + Equity | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B | $75.61B | $71.87B | $63.94B | · | $57.92B | $54.81B | $53.16B | · | $47.46B |
Flujo de Efectivo 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $534M | $509M | $586M | $470M | $478M | $463M | $485M | $467M | $414M | $401M | $387M | $411M | $366M | $362M | $375M | $363M | |
| Stock-based Comp | $201M | $161M | $136M | $151M | $185M | $154M | $142M | $133M | $211M | $159M | $121M | $216M | $162M | $131M | $93M | $85M | |
| Other Non-cash | · | $-2.73B | · | · | · | $-1.71B | · | · | · | $-1.64B | · | · | · | $-108M | · | · | |
| Operating Cash Flow | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B | $3.71B | $1.47B | $1.17B | $-312M | $2.19B | $632M | $1.73B | $1.66B | $2.60B | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $617M | |
| Investing Cash Flow | $-15.40B | $-3.92B | $-2.80B | $-2.98B | $-1.83B | $-3.35B | $-1.92B | $-4.00B | $-2.20B | $-1.18B | $-2.92B | $-3.08B | $-459M | $-689M | $-944M | $-1.34B | |
| Debt Issued | $8.94B | $0 | $-200.0K | $6.71B | $0 | $6.46B | $-100.0K | $4.96B | $0 | $6.45B | $500.0K | $0 | $0 | $3.96B | $0 | $0 | |
| Net Debt Issued | · | $-750M | · | · | · | $6.46B | · | · | · | $6.45B | · | · | · | $3.96B | · | · | |
| Stock Repurchased | $1.60B | $2.36B | $1.51B | $708M | $692M | $1.20B | $2.05B | $446M | $0 | $0 | $0 | $0 | $0 | $750M | $0 | $0 | |
| Net Stock Activity | · | $-2.36B | · | · | · | $-1.20B | · | · | · | $0 | · | · | · | $-750M | · | · | |
| Dividends Paid | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B | $1.17B | $1.17B | $1.17B | $1.02B | $1.02B | $1.02B | $1.02B | $884M | $882M | |
| Financing Cash Flow | $8.43B | $-3.47B | $-2.88B | $531M | $-1.24B | $1.38B | $-226M | $211M | $1.56B | $-311M | $3.55B | $572M | $-1.03B | $412M | $-1.14B | $-1.26B | |
| Net Change in Cash | $3.67B | $-1.99B | $-2.52B | $6.42B | $283M | $-175M | $-101M | $145M | $763M | $-358M | $438M | $-314M | $-851M | $1.48B | $-550M | $-6M |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 30.9% | 37.4% | · | 31.7% | 36.4% | 21.7% | · | 8.5% | 26.2% | 25.6% | · | -0.60% | 21.2% | 19.3% | · | 20.9% | |
| Pretax Margin | 40.2% | 44.7% | · | 41.1% | 43.6% | 27.2% | · | 13.9% | 31.1% | 28.9% | · | 4.5% | 25.1% | 22.0% | · | 22.6% | |
| EBITDA Margin | · | 2.6% | · | · | · | 3.6% | · | · | · | 4.6% | · | · | · | 5.2% | · | · | |
| ROA | 5.8% | 7.2% | · | 5.9% | 6.6% | 3.6% | · | 1.5% | 4.7% | 3.8% | · | -0.11% | 3.5% | 2.7% | · | 3.0% | |
| ROE | 27.2% | 31.5% | · | 29.4% | 35.6% | 19.3% | · | 7.6% | 24.1% | 18.7% | · | -0.54% | 18.0% | 13.1% | · | 16.3% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | 1.5 | · | 1.5 | 1.3 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.0 | 1.1 | 1.3 | · | 1.1 | |
| Quick Ratio | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.6 | · | 0.5 | 0.5 | 0.7 | · | 0.6 | |
| Debt / Equity | 1.4 | 1.3 | · | 1.7 | 1.9 | 2.2 | · | 2.0 | 1.7 | 1.9 | · | 1.6 | 1.6 | 1.7 | · | 1.4 | |
| LT Debt / Equity | 1.4 | 1.3 | · | 1.7 | 1.9 | 2.2 | · | 2.0 | 1.7 | 1.9 | · | 1.6 | 1.6 | 1.7 | · | 1.4 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.2 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.4 | 0.4 | 0.3 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.0 | · | 1.1 |
Valoración (TTM) 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.93B | $65.69B | · | $57.33B | $51.03B | $44.24B | · | $41.01B | $37.88B | $33.54B | · | $31.71B | $28.70B | $28.20B | · | $28.01B | |
| Net Income TTM | $25.73B | $21.40B | · | $14.97B | $12.36B | $8.94B | · | $6.12B | $6.92B | $5.29B | · | $4.50B | $5.51B | $5.65B | · | $5.42B | |
| P/E | 41.8 | 38.6 | · | 45.9 | 56.9 | 83.5 | · | 130.9 | 118.4 | 132.8 | · | 107.6 | 76.9 | 54.9 | · | 54.1 | |
| Earnings Yield | 2.4% | 2.6% | · | 2.2% | 1.8% | 1.2% | · | 0.76% | 0.84% | 0.75% | · | 0.93% | 1.3% | 1.8% | · | 1.8% | |
| Payout Ratio | · | 20.9% | · | · | · | 48.8% | · | · | · | 52.1% | · | · | · | 75.6% | · | · |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Beneficio neto | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS Diluido | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 1.5 | 2.3 | 2.3 | 1.5 | 1.7 |
| Ratio corriente | 1.6 | 1.2 | 0.9 | 1.1 | 1.2 |
| Ratio Rápido | 0.7 | 0.5 | 0.4 | 0.5 | 0.7 |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Three Center-Stage AI Players Join Eli Lilly On Elite Screen
- Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
- Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
- SPYM, GOOGL, LLY, BRK.B: Large Inflows Detected at ETF
- Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
- "Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.
- Ozempic-maker sues rival, accusing it of false advertising
- The market for psychedelic drugs to treat mental health conditions gets a big buy signal
- Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray
- AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 5 055 declarantes · $618.4B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 386 (+102 vs trimestre anterior) | 87 (-139 vs trimestre anterior) | 2 157 (+233 vs trimestre anterior) | 1 477 (-243 vs trimestre anterior) | +108.0M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| LILLY ENDOWMENT INC | $108 400 858 723 | 90 376 978 | 17,53% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $64 204 130 146 | 53 528 868 | 10,38% | Acciones |
| STATE STREET CORP | $43 438 261 820 | 36 215 754 | 7,02% | Acciones |
| Capital Research Global Investors | $25 037 481 632 | 20 873 140 | 4,05% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $25 019 170 646 | 20 859 217 | 4,05% | Acciones |
| FMR LLC | $23 272 664 162 | 19 403 104 | 3,76% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $21 252 395 665 | 17 790 304 | 3,44% | Acciones |
| Capital World Investors | $19 076 022 904 | 15 902 642 | 3,08% | Acciones |
| NORGES BANK | $13 759 156 895 | 11 471 413 | 2,22% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $12 172 183 865 | 10 148 307 | 1,97% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $11 002 256 246 | 9 172 904 | 1,78% | Acciones |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $8 853 660 913 | 7 381 557 | 1,43% | Acciones |
| UBS Group AG | $8 756 297 182 | 7 300 382 | 1,42% | Opción de compra |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $7 198 575 852 | 6 001 664 | 1,16% | Acciones |
| Capital International Investors | $6 879 841 625 | 5 734 768 | 1,11% | Acciones |
| JENNISON ASSOCIATES LLC | $6 415 075 179 | 5 348 436 | 1,04% | Acciones |
| Fisher Asset Management, LLC | $6 073 333 633 | 5 063 516 | 0,98% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $5 508 155 583 | 4 592 311 | 0,89% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $4 288 683 267 | 3 575 603 | 0,69% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $3 916 450 563 | 4 258 076 | 0,63% | Acciones |
| JANE STREET GROUP, LLC | $3 018 245 652 | 2 516 400 | 0,49% | Opción de venta |
| AMERICAN CENTURY COMPANIES INC | $2 824 462 145 | 2 354 837 | 0,46% | Acciones |
| CITADEL ADVISORS LLC | $2 817 700 956 | 2 349 200 | 0,46% | Opción de venta |
| Swiss National Bank | $2 716 888 865 | 2 265 150 | 0,44% | Acciones |
| UBS Group AG | $2 674 269 518 | 2 229 617 | 0,43% | Acciones |
| BlackRock, Inc. | $2 610 637 358 | 2 176 565 | 0,42% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $2 568 591 611 | 2 141 447 | 0,42% | Acciones |
| JANE STREET GROUP, LLC | $2 536 674 507 | 2 114 900 | 0,41% | Opción de compra |
| Mitsubishi UFJ Asset Management Co., Ltd. | $2 415 287 393 | 2 013 696 | 0,39% | Acciones |
| GOLDMAN SACHS GROUP INC | $2 358 324 528 | 1 966 204 | 0,38% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $2 273 837 414 | 1 895 765 | 0,37% | Acciones |
| CITADEL ADVISORS LLC | $2 256 727 545 | 1 881 500 | 0,36% | Opción de compra |
| Legal & General Group Plc | $2 202 867 142 | 1 836 595 | 0,36% | Acciones |
| FIFTH THIRD BANCORP | $2 099 946 659 | 1 750 788 | 0,34% | Acciones |
| BANK OF AMERICA CORP /DE/ | $2 060 238 592 | 1 717 681 | 0,33% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $2 057 106 410 | 1 715 070 | 0,33% | Acciones |
| Vanguard Global Advisers, LLC | $2 048 187 448 | 1 707 634 | 0,33% | Acciones |
| National Pension Service | $2 018 379 214 | 1 682 782 | 0,33% | Acciones |
| NEUBERGER BERMAN GROUP LLC | $1 973 413 342 | 1 645 037 | 0,32% | Acciones |
| AMERIPRISE FINANCIAL INC | $1 955 279 981 | 1 630 180 | 0,32% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $1 867 073 519 | 1 556 634 | 0,30% | Acciones |
| VANGUARD GROUP INC | $1 858 925 581 | 1 729 748 | 0,30% | Acciones |
| SAPIENT CAPITAL LLC | $1 736 223 301 | 1 447 540 | 0,28% | Acciones |
| California Public Employees Retirement System | $1 727 998 411 | 1 440 683 | 0,28% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $1 604 453 190 | 1 337 665 | 0,26% | Acciones |
| RHUMBLINE ADVISERS | $1 599 208 304 | 1 333 307 | 0,26% | Acciones |
| LPL Financial LLC | $1 529 042 537 | 1 274 807 | 0,25% | Acciones |
| US BANCORP \DE\ | $1 525 382 299 | 1 271 756 | 0,25% | Acciones |
| PeakShares LLC | $1 459 706 000 | 1 217 | 0,24% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $1 410 361 452 | 1 175 866 | 0,23% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $1 378 916 702 | 1 149 643 | 0,22% | Acciones |
| APG Asset Management N.V. | $1 269 741 378 | 1 210 321 | 0,21% | Acciones |
| TD Asset Management Inc | $1 203 590 823 | 1 003 469 | 0,19% | Acciones |
| COMERICA BANK | $1 187 462 066 | 1 104 945 | 0,19% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1 182 373 533 | 1 285 510 | 0,19% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $1 153 247 147 | 961 496 | 0,19% | Acciones |
| NORDEA INVESTMENT MANAGEMENT AB | $1 140 281 246 | 946 590 | 0,18% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1 117 172 877 | 1 214 622 | 0,18% | Acciones |
| Bank Julius Baer & Co. Ltd, Zurich | $1 100 986 977 | 913 248 | 0,18% | Acciones |
| Ensign Peak Advisors, Inc | $1 073 804 101 | 895 262 | 0,17% | Acciones |
| PNC Financial Services Group, Inc. | $1 055 920 599 | 880 352 | 0,17% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $1 038 211 015 | 865 587 | 0,17% | Acciones |
| Caisse de depot et placement du Quebec | $966 511 489 | 805 809 | 0,16% | Acciones |
| Robeco Institutional Asset Management B.V. | $910 055 515 | 758 740 | 0,15% | Acciones |
| Pictet Asset Management Holding SA | $905 835 797 | 754 985 | 0,15% | Acciones |
| BARCLAYS PLC | $904 852 390 | 754 402 | 0,15% | Acciones |
| Grantham, Mayo, Van Otterloo & Co. LLC | $892 337 542 | 743 966 | 0,14% | Acciones |
| PRUDENTIAL FINANCIAL INC | $879 194 184 | 733 010 | 0,14% | Acciones |
| CITADEL ADVISORS LLC | $874 462 433 | 729 065 | 0,14% | Acciones |
| JONES FINANCIAL COMPANIES LLLP | $874 355 284 | 723 732 | 0,14% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $871 024 867 | 726 199 | 0,14% | Acciones |
| AVIVA PLC | $861 503 791 | 718 261 | 0,14% | Acciones |
| LAZARD ASSET MANAGEMENT LLC | $828 834 772 | 691 024 | 0,13% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $819 673 670 | 683 386 | 0,13% | Acciones |
| CIBC Bancorp USA Inc. | $819 454 832 | 683 299 | 0,13% | Acciones |
| POLEN CAPITAL MANAGEMENT LLC | $799 914 391 | 666 912 | 0,13% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $792 908 390 | 661 071 | 0,13% | Acciones |
| Korea Investment CORP | $790 364 399 | 658 950 | 0,13% | Acciones |
| Bahl & Gaynor LLC | $786 973 674 | 656 123 | 0,13% | Acciones |
| ROYAL LONDON ASSET MANAGEMENT LTD | $774 668 656 | 645 864 | 0,13% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $729 268 278 | 610 128 | 0,12% | Acciones |
| GOLDMAN SACHS GROUP INC | $697 588 488 | 581 600 | 0,11% | Opción de venta |
| MACKENZIE FINANCIAL CORP | $696 221 138 | 580 460 | 0,11% | Acciones |
| Ninety One UK Ltd | $684 160 837 | 570 405 | 0,11% | Acciones |
| WOLVERINE TRADING, LLC | $675 581 649 | 929 900 | 0,11% | Opción de venta |
| WOLVERINE TRADING, LLC | $665 773 764 | 916 400 | 0,11% | Opción de compra |
| Quantinno Capital Management LP | $656 743 405 | 547 546 | 0,11% | Acciones |
| Goelzer Investment Management, Inc. | $644 679 302 | 537 488 | 0,10% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $631 148 000 | 526 202 | 0,10% | Acciones |
| PARNASSUS INVESTMENTS, LLC | $630 257 285 | 525 464 | 0,10% | Acciones |
| BANK OF MONTREAL /CAN/ | $623 256 213 | 519 627 | 0,10% | Acciones |
| Employees Provident Fund Board | $621 615 392 | 518 259 | 0,10% | Acciones |
| CITIGROUP INC | $614 947 761 | 512 700 | 0,10% | Opción de venta |
| Assenagon Asset Management S.A. | $600 944 416 | 501 025 | 0,10% | Acciones |
| Aberdeen Group plc | $582 286 083 | 485 469 | 0,09% | Acciones |
| Clearbridge Investments, LLC | $579 491 277 | 483 139 | 0,09% | Acciones |
| PFA Pension, Forsikringsaktieselskab | $579 482 599 | 483 132 | 0,09% | Acciones |
| AMF Tjanstepension AB | $573 419 896 | 478 077 | 0,09% | Acciones |
| DEUTSCHE BANK AG\ | $572 292 432 | 477 137 | 0,09% | Acciones |
| STOREBRAND ASSET MANAGEMENT AS | $565 821 507 | 471 742 | 0,09% | Acciones |
Informantes de la empresa 83 insiders · 48 directivos · 30 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| David A Ricks | President, Chair, and CEO | 12 de agosto de 2025 P | 546 601 | 0 | 0 | $0 |
| Lucas Montarce | EVP & CFO | 15 de agosto de 2025 P | 14 685 | 0 | 0 | $0 |
| Anat Ashkenazi | EVP & CFO | 12 de febrero de 2024 A | 42 330 | 0 | 0 | $0 |
| Derica W Rice | EVP-Global Services and CFO | 1 de febrero de 2017 M | 38 292 | 0 | 0 | $0 |
| Charles E Golden | Exec. Vice President and CFO | 28 de abril de 2006 F | 85 249 | 0 | 0 | $0 |
| Maria A Crowe | President, Mfg. Operations | 1 de febrero de 2017 M | 113 581 | 0 | 0 | $0 |
| Frank M Deane | President, Mfg. Operations | 1 de febrero de 2012 M | 33 995 | 0 | 0 | $0 |
| Deirdre P Connelly | President, U.S. Operations | 27 de enero de 2009 A | 53 681 | 0 | 0 | $0 |
| Lorenzo Tallarigo | President, Internat'l Opers. | 31 de marzo de 2008 F | 64 458 | 0 | 0 | $0 |
| Scott A Canute | President, Mfg. Operations | 1 de febrero de 2007 F | 25 367 | 0 | 0 | $0 |
| Patrik Jonsson | EVP & President, LLY Int'l | 17 de agosto de 2026 S | 54 147 | 0 | 1 | $-7 638 150 |
| Melissa Seymour | EVP, Global Quality | 1 de agosto de 2026 M | 1 067 | 0 | 0 | $0 |
| Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | 10 de junio de 2026 S | 29 804 | 0 | 1 | $-2 876 925 |
| Edgardo Hernandez | EVP & Pres., Mfg. Operations | 5 de septiembre de 2025 G | 39 731 | 0 | 0 | $0 |
| Kenneth L. Custer | EVP & President, Card Met Hlth | 27 de agosto de 2025 I | — | 0 | 0 | $0 |
| Jacob Van Naarden | EVP & Pres., Lilly Oncology | 13 de agosto de 2025 P | 20 562 | 0 | 0 | $0 |
| Daniel Skovronsky | EVP, CSO & Pres. LRL & LLY Imm | 12 de agosto de 2025 P | 137 660 | 0 | 0 | $0 |
| Eric Dozier | EVP, Chief People Officer | 1 de marzo de 2025 M | 9 839 | 0 | 0 | $0 |
| Diogo Rau | EVP & CIDO | 10 de febrero de 2025 A | 19 719 | 0 | 0 | $0 |
| Anne E. White | EVP & Pres, Lilly Neuroscience | 10 de febrero de 2025 A | 74 210 | 0 | 0 | $0 |
| Johna Norton | EVP, Global Quality | 3 de junio de 2024 S | 25 428 | 0 | 0 | $0 |
| Alonzo Weems | EVP, ERM & CECO | 12 de febrero de 2024 A | 7 951 | 0 | 0 | $0 |
| Michael B Mason | EVP & Pres., Lilly Diabetes | 10 de febrero de 2023 A | 39 284 | 0 | 0 | $0 |
| Leigh Ann Pusey | EVP, Corp. Affairs & Comm. | 10 de febrero de 2023 A | 31 641 | 0 | 0 | $0 |
| Stephen F Fry | SVP, HR & Diversity | 9 de febrero de 2022 A | 152 631 | 0 | 0 | $0 |
| Myles O'Neill | SVP & Pres., Mfg. Operations | 8 de febrero de 2021 A | 72 533 | 0 | 0 | $0 |
| Alfonso G Zulueta | SVP & President, Lilly Int'l | 8 de febrero de 2021 A | 56 947 | 0 | 0 | $0 |
| Melissa S Barnes | Chief Eth/Cmpl Ofcr & SVP, ERM | 8 de febrero de 2021 A | 34 616 | 0 | 0 | $0 |
| Michael J Harrington | Senior VP and General Counsel | 2 de enero de 2020 A | 59 500 | 0 | 0 | $0 |
| Christi Shaw | SVP and Pres., Lilly Bio-Meds | 3 de mayo de 2019 S | 500 | 0 | 0 | $0 |
| Enrique A Conterno | SVP&Pres, LillyDiab & LillyUSA | 4 de febrero de 2019 A | 157 962 | 0 | 0 | $0 |
| Jeffrey N Simmons | SVP&Pres. Elanco Animal Health | 1 de mayo de 2018 M | 135 458 | 0 | 0 | $0 |
| Susan Mahony | SVP & Pres., Lilly Oncology | 16 de abril de 2018 S | 40 685 | 0 | 0 | $0 |
| Jan M Lundberg | EVP,Science&Tech and Pres. LRL | 9 de febrero de 2018 A | 198 126 | 0 | 0 | $0 |
| Fionnuala M Walsh | SVP, Global Quality | 1 de febrero de 2017 M | 67 144 | 0 | 0 | $0 |
| Barton R Peterson | Sr. VP, Corp. Affairs & Comm. | 1 de febrero de 2017 M | 108 312 | 0 | 0 | $0 |
| Jacques Tapiero | SVP&Pres., Emerging Markets | 28 de enero de 2014 A | 55 384 | 0 | 0 | $0 |
| Arnold C Hanish | Chief Accounting Officer | 29 de agosto de 2012 G | 17 611 | 0 | 0 | $0 |
| Bryce D. Carmine | EVP and Pres, Lilly Bio-Meds | 1 de febrero de 2012 M | 102 647 | 0 | 0 | $0 |
| Robert A Armitage | Sr. VP and General Counsel | 1 de febrero de 2012 M | 97 063 | 0 | 0 | $0 |
| Anne Nobles | Chief Eth/Cmpl Ofcr & SVP, ERM | 26 de enero de 2012 A | 23 536 | 0 | 0 | $0 |
| Steven M Paul | EVP, Science and Technology | 1 de febrero de 2010 M | 38 897 | 0 | 0 | $0 |
| Anthony John Murphy | Senior VP, Human Resources | 2 de febrero de 2009 F | 15 231 | 0 | 0 | $0 |
| Gino Santini | Sr.VP, Corp. Strategy & BD | 2 de febrero de 2009 F | 102 174 | 0 | 0 | $0 |
| Alex M Azar II | Sr. VP, Corp. Affairs & Comm. | 27 de enero de 2009 A | 5 000 | 0 | 0 | $0 |
| Sidney Taurel | Chairman | 31 de diciembre de 2008 F | 341 806 | 0 | 0 | $0 |
| Gerhard N Mayr | EVP, Pharmaceutical Operations | 17 de febrero de 2004 A | — | 0 | 0 | $0 |
| Pedro P Granadillo | Senior Vice President | 17 de febrero de 2004 A | — | 0 | 0 | $0 |
| Juan R Luciano | Consejero | 17 de agosto de 2026 A | 16 918 | 0 | 0 | $0 |
| Erik J Fyrwald | Consejero | 17 de agosto de 2026 A | 75 418 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| ELI LILLY AND COMPANY, SHENANDOAH ACQUISITION CORPORATION ×15 presentaciones | 14 de agosto de 2023 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 324 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IHE · iShares Trust | 21,36% | 290 244 SH | 8 de agosto de 2026 | Diario |
| MEDI · Harbor ETF Trust | 20,10% | 5 929 NS | 30 de abril de 2026 | N-PORT |
| IYH · iShares Trust | 15,48% | 478 046 SH | 8 de agosto de 2026 | Diario |
| ELIL · Direxion Shares ETF Trust | 15,27% | 3 512 NS | 30 de abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 14,19% | 2 414 193 SH | 8 de agosto de 2026 | Diario |
| GDOC · Goldman Sachs ETF Trust | 13,28% | 2 417 NS | 31 de mayo de 2026 | N-PORT |
| RXL · ProShares Trust | 12,67% | 8 263 NS | 31 de mayo de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 12,13% | 370 443 NS | 30 de abril de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 11,52% | 5 413 NS | 31 de mayo de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 10,68% | 15 801 NS | 30 de abril de 2026 | N-PORT |
| IXJ · iShares Trust | 10,58% | 369 006 SH | 8 de agosto de 2026 | Diario |
| SNPG · DBX ETF Trust | 7,01% | 852 NS | 29 de mayo de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,81% | 811 NS | 30 de abril de 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 5,19% | 15 945 NS | 30 de abril de 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,03% | 21 491 SH | 8 de agosto de 2026 | Diario |
| JGRW · Trust for Professional Managers | 4,90% | 4 253 NS | 31 de mayo de 2026 | N-PORT |
| CANC · Tema ETF Trust | 4,82% | 7 684 NS | 31 de mayo de 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 4,78% | 2 923 NS | 31 de mayo de 2026 | N-PORT |
| EGGS · Tidal Trust III | 4,43% | 2 254 NS | 31 de mayo de 2026 | N-PORT |
| FLAG · Global X Funds | 4,25% | 75 NS | 30 de abril de 2026 | N-PORT |
| CARK · Advisors' Inner Circle Fund II | 4,24% | 14 041 NS | 30 de abril de 2026 | N-PORT |
| DUHP · Dimensional ETF Trust | 4,21% | 511 432 NS | 30 de abril de 2026 | N-PORT |
| PJFG · PGIM ETF Trust | 4,16% | 5 851 NS | 29 de mayo de 2026 | N-PORT |
| VIG · VANGUARD SPECIALIZED FUNDS | 4,14% | 4 469 091 SH | 8 de agosto de 2026 | Diario |
| XT · iShares Trust | 4,09% | 134 371 SH | 8 de agosto de 2026 | Diario |
| AMOM · Exchange Listed Funds Trust | 4,05% | 1 321 NS | 30 de abril de 2026 | N-PORT |
| MBCC · Northern Lights Fund Trust IV | 4,01% | 6 688 NS | 31 de mayo de 2026 | N-PORT |
| PFM · Invesco Exchange-Traded Fund Trust | 3,95% | 26 928 SH | 8 de agosto de 2026 | Diario |
| CGUS · Capital Group Core Equity ETF | 3,92% | 384 824 NS | 31 de mayo de 2026 | N-PORT |
| SEMG · EA Series Trust | 3,87% | 2 506 NS | 30 de abril de 2026 | N-PORT |
| GFGF · EA Series Trust | 3,86% | 1 296 NS | 29 de mayo de 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,84% | 716 NS | 31 de mayo de 2026 | N-PORT |
| BKCG · BNY Mellon ETF Trust II | 3,79% | 4 808 NS | 30 de abril de 2026 | N-PORT |
| TOPT · iShares Trust | 3,76% | 21 397 SH | 8 de agosto de 2026 | Diario |
| QUAL · iShares Trust | 3,71% | 1 492 544 SH | 8 de agosto de 2026 | Diario |
| GARP · iShares Trust | 3,71% | 87 685 SH | 8 de agosto de 2026 | Diario |
| HFGO · Hartford Funds Exchange-Traded Trust | 3,66% | 7 105 NS | 30 de abril de 2026 | N-PORT |
| RILA · Spinnaker ETF Series | 3,61% | 1 620 NS | 30 de abril de 2026 | N-PORT |
| AGNG · Global X Funds | 3,58% | 2 652 NS | 31 de mayo de 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 3,56% | 331 NS | 31 de mayo de 2026 | N-PORT |
| EGGY · Tidal Trust III | 3,54% | 4 039 NS | 31 de mayo de 2026 | N-PORT |
| CGCV · Capital Group Conservative Equity E… | 3,52% | 55 867 NS | 31 de mayo de 2026 | N-PORT |
| GDIV · Harbor ETF Trust | 3,51% | 8 487 NS | 30 de abril de 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 3,45% | 8 953 NS | 31 de mayo de 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 3,44% | 9 741 NS | 31 de marzo de 2026 | N-PORT |
| GGUS · Goldman Sachs ETF Trust | 3,43% | 14 301 NS | 31 de mayo de 2026 | N-PORT |
| GROZ · Zacks Trust | 3,41% | 2 787 NS | 31 de mayo de 2026 | N-PORT |
| MGK · VANGUARD WORLD FUND | 3,39% | 943 950 SH | 8 de agosto de 2026 | Diario |
| IWY · iShares Trust | 3,35% | 463 234 SH | 8 de agosto de 2026 | Diario |
| NEWZ · EA Series Trust | 3,33% | 675 NS | 30 de abril de 2026 | N-PORT |